Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 217

1.

American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.

Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG.

J Clin Oncol. 1999 Jun;17(6):1939-55. Review.

PMID:
10561236
2.

American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.

Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, Burstein HJ, Eisen A, Lipkus I, Pfister DG; American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group.

J Clin Oncol. 2002 Aug 1;20(15):3328-43. Review.

PMID:
12149307
3.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP.

J Clin Oncol. 2002 Aug 1;20(15):3317-27. Review.

PMID:
12149306
4.

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM; American Society of Clinical Oncology.

J Clin Oncol. 2009 Jul 1;27(19):3235-58. doi: 10.1200/JCO.2008.20.5179. Epub 2009 May 26.

5.

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG, Anderson GL, McCaskill-Stevens W.

J Clin Oncol. 2011 Jun 10;29(17):2327-33. doi: 10.1200/JCO.2010.33.0258. Epub 2011 May 2. Erratum in: J Clin Oncol. 2013 Nov 10;31(32):4167.

6.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.

7.

Breast cancer chemoprevention.

Mamounas EP.

Hematol Oncol Clin North Am. 2000 Jun;14(3):727-38. Review. No abstract available.

PMID:
11203331
8.

Overview of the main outcomes in breast-cancer prevention trials.

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P.

Lancet. 2003 Jan 25;361(9354):296-300. Review.

PMID:
12559863
9.

Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Levine M, Moutquin JM, Walton R, Feightner J; Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

CMAJ. 2001 Jun 12;164(12):1681-90. Review.

10.

Chemoprevention of breast cancer.

Dalton RR, Kallab AM.

South Med J. 2001 Jan;94(1):7-15. Review.

PMID:
11213947
11.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N.

J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041. Review.

12.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP).

JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.

PMID:
16754727
13.

Future possibilities in the prevention of breast cancer: breast cancer prevention trials.

Cuzick J.

Breast Cancer Res. 2000;2(4):258-63. Epub 2000 May 19. Review.

14.
15.

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.

Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN.

Ann Intern Med. 2002 Jul 2;137(1):59-69. Review.

PMID:
12093250
17.

Breast cancer prevention trials.

Rhodes DJ, Hartmann LC, Perez EA.

Curr Oncol Rep. 2000 Nov;2(6):558-65. Review.

PMID:
11122893
18.

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.

Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SM.

J Clin Oncol. 2013 Aug 10;31(23):2942-62. doi: 10.1200/JCO.2013.49.3122. Epub 2013 Jul 8. Review. Erratum in: J Clin Oncol. 2013 Dec 1;31(34):4383.

PMID:
23835710
19.

Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.

Nelson HD, Smith ME, Griffin JC, Fu R.

Ann Intern Med. 2013 Apr 16;158(8):604-14. doi: 10.7326/0003-4819-158-8-201304160-00005. Review.

PMID:
23588749
20.

Chemoprevention or mastectomy for women at high risk of developing breast cancer.

Sismondi P, D'Alonzo M, Pecchio S, Bounous VE, Robba E, Biglia N.

Maturitas. 2015 Nov;82(3):271-3. doi: 10.1016/j.maturitas.2015.07.002. Epub 2015 Jul 26. Review.

PMID:
26276104

Supplemental Content

Support Center